Last updated on: 02/03/2021
Name of organisation
1) Department/Research group
2) Organisation/affiliationJulius Clinical Research
Short Name in the inventoryJulius Clinical Research
Administrative Contact
Title Dr
Last name Franks
First name Billy
Address line 1Broederplein 41-43
Address line 2
Address line 3
CityZeist
Postcode3703CD
CountryNetherlands
Phone number (incl. country code)+31631671676
Alternative phone number
Fax number (incl. country code)Netherlands
Scientific Contact
Title Dr
Last name Franks
First name Billy
Address line 1Broederplein 41-43
Address line 2
Address line 3
CityZeist
Postcode3703CD
CountryNetherlands
Phone number (incl. country code)+31631671676
Alternative phone number
Fax number (incl. country code)Netherlands
2. Description
Julius Clinical’s RWE specialists and data scientists are academic thought leaders in real-world evidence, real-world data and the creation of tailor-made studies. This includes being leading members of the EU IMI GetReal Initiative. Through this, we combine established expertise in RWE methodologies with Julius Clinical’s know-how in data sourcing, study execution and managing extensive scientific networks. As a key partner in the IMI Trials@Home and H2020 COVID-RED projects, Julius Clinical is also at the forefront of technology-driven solutions for decentralized clinical studies and has the knowledge, expertise and resources to design and conduct studies that include such approaches.
3. Category
For profit organisation
4. Available resources
In houseVia Contacts/Network
Epidemiologist/Pharmacoepidemiologist
Yes
Yes
Statistician
Yes
Yes
Clinician
Yes
Yes
Clinical Pharmacologist
No
Yes
Pharmacist
No
Yes
Geneticist/Pharmacogeneticist
No
Yes
IT specialist
Yes
Yes
Ethics expertise
Yes
Yes
Legal expertise
Yes
Yes
Regulatory expertise
Yes
Yes
Data Scientists
Yes
Yes
Data Managers
Yes
Yes
Project Managers
Yes
Yes
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Devices
Disorders of the central nervous system
Ear, nose and oropharynx disorders
Endocrine disorders
Immunological products and vaccines
Infectious diseases
Liver disease
Malignant disease
Paediatrics
Renal impairment
Respiratory diseases
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Interventional Clinical Trial
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Greater than 15000
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
Yes
System used:
Castor, LifeSphere, Your Research, etc.
Interactive voice response systems
Yes
Call centre
Yes
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
PHARMO Database Network1
PedNet1
JGPN1
LRJG1
ENCALS - Amyotrophic lateral sclerosis1
11. Registries established by centre
Disease RegistryReSViNET
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Networks registered with ENCePP
VAC4EU
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
No
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
MacDonald TM, Hawkey CJ, Ford I, McMurray JJV, Scheiman JM, Hallas J, Findlay
E, Grobbee DE, Hobbs FDR, Ralston SH, Reid DM, Walters MR, Webster J, Ruschitzka
F, Ritchie LD, Perez-Gutthann S, Connolly E, Greenlaw N, Wilson A, Wei L,
Mackenzie IS. Randomized trial of switching from prescribed non-selective non-
steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs.
Celecoxib Outcome Trial (SCOT). Eur Heart J. 2017 Jun 14;38(23):1843-1850. doi:
10.1093/eurheartj/ehw387. Erratum in: Eur Heart J. 2016 Dec 24;: PMID: 27705888;
PMCID: PMC5837371.
Zuidgeest MGP, Goetz I, Groenwold RHH, Irving E, van Thiel GJMW, Grobbee DE;
GetReal Work Package 3. Series: Pragmatic trials and real world evidence: Paper
1. Introduction. J Clin Epidemiol. 2017 Aug;88:7-13. doi:
10.1016/j.jclinepi.2016.12.023. Epub 2017 May 24. PMID: 28549929.
Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, Maggioni A,
Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J, Castro
Conde A, Cifkova R, Crowley J, Davletov K, Deckers J, De Smedt D, De Sutter J,
Dilic M, Dolzhenko M, Dzerve V, Erglis A, Fras Z, Gaita D, Gotcheva N,
Heuschmann P, Hasan-Ali H, Jankowski P, Lalic N, Lehto S, Lovic D, Mancas S,
Mellbin L, Milicic D, Mirrakhimov E, Oganov R, Pogosova N, Reiner Z, Stöerk S,
Tokgözoğlu L, Tsioufis C, Vulic D, Wood D; EUROASPIRE Investigators*. Lifestyle
and impact on cardiovascular risk factor control in coronary patients across 27
countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V
registry. Eur J Prev Cardiol. 2019 May;26(8):824-835. doi:
10.1177/2047487318825350. Epub 2019 Feb 10. PMID: 30739508.
Bowman L, Baras A, Bombien R, Califf RM, Chen Z, Gale CP, Gaziano JM, Grobbee
DE, Maggioni AP, Muse ED, Roden DM, Schroeder S, Wallentin L, Casadei B.
Understanding the use of observational and randomized data in cardiovascular
medicine. Eur Heart J. 2020 Jul 14;41(27):2571-2578. doi:
10.1093/eurheartj/ehaa020. PMID: 32016367.
